Modeling The Cost-Effectiveness of The All Oral, Direct-Acting Antiviral Regimen Daclatasvir Plus Sofosbuvir In Patients Co-Infected With Hepatitis C Virus (Hcv) And Hiv
Abstract
Authors
P McEwan T Ward S Webster A Kalsekar M Brenner Y Yuan